Indivior PLC (NASDAQ:INDV) Stock Has Average Target Price of $45.17

Shares of Indivior PLC (NASDAQ:INDV) have received a consensus rating of “Moderate Buy” from the seven research firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $45.17.

Several equities analysts recently weighed in on the company. Barclays lowered their target price on Indivior from $46.00 to $43.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 5th. Weiss Ratings raised Indivior from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Friday, September 4th. Craig Hallum reaffirmed a “buy” rating and set a $53.00 price objective on shares of Indivior in a research report on Tuesday, August 4th. Finally, Zacks Research downgraded Indivior from a “strong-buy” rating to a “hold” rating in a research note on Monday, June 29th.

Indivior Trading Up 0.3%

INDV opened at $36.00 on Friday. The firm’s 50 day simple moving average is $37.22 and its two-hundred day simple moving average is $36.23. The company has a market capitalization of $4.25 billion, a PE ratio of 12.90 and a beta of 0.82. Indivior has a 1-year low of $22.56 and a 1-year high of $42.81.

Indivior (NASDAQ:INDV) last issued its quarterly earnings data on Tuesday, June 30th. The company reported $5.75 earnings per share (EPS) for the quarter. The firm had revenue of $343.00 million during the quarter. Indivior had a net margin of 26.65% and a negative return on equity of 283.11%. Equities analysts forecast that Indivior will post 3.66 earnings per share for the current fiscal year.

Indivior Dividend Announcement

The company also recently declared a special dividend, which will be paid on Friday, November 6th. Shareholders of record on Friday, October 30th will be issued a dividend of $8.13 per share. The ex-dividend date of this dividend is Friday, October 30th.

Insider Buying and Selling

In other Indivior news, insider Christian Heidbreder sold 18,586 shares of the company’s stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $41.14, for a total value of $764,628.04. Following the completion of the transaction, the insider directly owned 209,337 shares in the company, valued at $8,612,124.18. This represents a 8.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Woodrow D. Anderson acquired 1,500 shares of Indivior stock in a transaction dated Thursday, August 27th. The stock was purchased at an average cost of $35.69 per share, with a total value of $53,535.00. Following the completion of the purchase, the chief accounting officer owned 27,638 shares of the company’s stock, valued at approximately $986,400.22. This represents a 5.74% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 0.74% of the company’s stock.

Institutional Investors Weigh In On Indivior

A number of institutional investors have recently bought and sold shares of INDV. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in Indivior during the fourth quarter valued at $82,687,000. Assenagon Asset Management S.A. purchased a new position in shares of Indivior in the 2nd quarter worth $63,224,000. Newtyn Management LLC purchased a new position in shares of Indivior in the 2nd quarter worth $53,577,000. Hennion & Walsh Asset Management Inc. purchased a new position in shares of Indivior in the 2nd quarter worth $14,781,000. Finally, LSV Asset Management increased its holdings in shares of Indivior by 1,334.2% in the 4th quarter. LSV Asset Management now owns 291,134 shares of the company’s stock worth $10,446,000 after buying an additional 270,834 shares during the last quarter. Hedge funds and other institutional investors own 60.33% of the company’s stock.

About Indivior

Indivior plc is a specialty pharmaceutical company focused on developing and commercializing medicines for addiction and serious mental health disorders. Its portfolio is primarily centered on treatments for opioid use disorder, with an emphasis on products designed to support recovery, reduce illicit opioid use and address the risk of overdose.

The company’s key products include SUBOXONE sublingual film, a buprenorphine-and-naloxone treatment for opioid use disorder; SUBLOCADE, a long-acting injectable form of buprenorphine; and OPVEE, a nalmefene nasal spray intended for the emergency treatment of opioid overdose.